Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 25 March 2026
Lifileucel for previously treated unresectable or metastatic melanoma ID3863Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 July 2026
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cryoablation for Desmoid-type FibromatosisStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 19 February 2026Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC